Synchronized Glioma Insights: Trends, Blood Group Correlations, Staging Dynamics, and the Vanguard of Liquid Biopsy Advancements

Ryan Adnan Sheikh ¹, Salma Naqvi ², Ayman Mohammed Al-Sulami ¹

⁰Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.

Cns & Neurological Disorders Drug Targets +

|

July 3, 2024

View abstract on PubMed

Summary

Liquid biopsy markers can help monitor glioma progression and grade tumors non-invasively. This study also suggests a link between glioma development and ABO blood group antigens.

Area Of Science

Neuro-oncology
Oncology
Biomarker Discovery

Background

Gliomas are aggressive, heterogeneous brain tumors with poor prognosis.
Current monitoring and grading rely on invasive tissue biopsies.
There is a need for non-invasive diagnostic and prognostic tools.

Purpose Of The Study

To compare liquid biopsy marker levels across different glioma grades.
To investigate the association between glioma and ABO blood group antigens.
To assess the potential of liquid biopsy in glioma management.

Main Methods

Analysis of liquid biopsy markers in 78 glioma patients.
Comparison of marker levels (ALT, LDH, lymphocytes, Urea, AST, Neutrophils, CRP) with glioma grade.
Correlation of patient blood groups with glioma incidence.

Main Results

Liquid biopsy marker levels (ALT, LDH, lymphocytes, Urea, AST, Neutrophils, CRP) significantly increased with glioma grade (II, III, IV).
Glioblastoma (grade IV) showed the highest levels of these biomarkers.
Blood group O+ was most frequent (53.8%) in glioblastoma patients.

Conclusions

Liquid biopsy offers a non-invasive method for assessing glioma status and tumor grade.
Elevated liquid biopsy markers correlate with glioma severity, indicating prognostic utility.
Evidence suggests a role for ABO blood group antigens in glioma development, warranting further research.

Keywords:

CRP LFT Liquid biopsy blood group correlations. glioma stages trends